Abstract
Background: Bioresorbable Scaffolds (BRS) are a novel approach to treat coronary stenoses using a temporary polymeric scaffold to maintain normal arterial curvature, allow return of vasomotion and enable positive remodelling. We aimed to determine the medium-term outcomes of patients undergoing percutaneous coronary intervention (PCI) with BRS. Methods: 83 consecutive patients treated with ABSORB BRS at Christchurch and St George's Hospitals between 18/08/2011-31/12/2014 were followed for Major Adverse Cardiac Events (MACE - death, non-fatal myocardial infarction (MI) and revascularisation). Results: Mean age: 53.6 years, 82% males, 22% STEMI and 25% NSTEMI. 85.5% had single vessel PCI. 110 BRS were deployed to treat 92 lesions (53% LAD), including 52% type-B and 45% type-C lesions. 3 were ostial lesions, 7 in-stent restenosis, and 5 bifurcation lesions. Overlap stenting to treat 18 lesions: 10=BVS/BVS, 8=BVS/drug eluting stent. Median overlap stent/scaffold length was 46mm (20-88mm). Device/procedural success rates were 100%. During a median follow-up of 15 months (2-42 months), MACE rate was 4.8%: two cases of sub-acute stent thrombosis (ST) and two cases of late ST including one death. Subgroup analysis of lesion types found MACE of 0% in type-AB lesions and 9.7% in type-C lesions. Conclusions: BRS implantation appears feasible in daily clinical practice with good device and procedural success. Early and late ST are seen following treatment of complicated type-C lesions. Larger randomised studies using multimodality imaging may help to understand role of BRS in such lesions.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call